Navigation Links
Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
Date:6/28/2009

S. MAMEDE DO CORONADO, Portugal, June 29 /PRNewswire/ -- Data presented today, in Budapest, demonstrated that add-on treatment with the novel, once-daily anti-epileptic Zebinix(R)* (eslicarbazepine acetate; ESL) resulted in a marked and sustained decrease in seizure frequency over the long-term(1).

Results from the one-year extension of a pivotal Eslicarbazepine Acetate phase III study were presented at the International Congress for Epilepsy in Budapest, Hungary. Patients not controlled with existing anti-epileptic drugs who were given eslicarbazepine acetate as an add-on treatment experienced a mean reduction in seizure frequency of more than 61% (95%CI: -68.2%, -55.5%)1. Nearly 65% of patients were classified as responders, meaning that they had achieved at least a 50% reduction in seizure frequency with Zebinix(R) treatment(1).

"These data continue to demonstrate the efficacy and safety of Zebinix(R) in the treatment of partial onset seizures", said Joyce Cramer, research scientist at Yale University School of Medicine, USA and President of The Epilepsy Therapy Project. "Epilepsy is a devastating condition that can be very difficult to manage and the availability of eslicarbazepine acetate adds an important new choice of therapy for patients who are in vital need of better seizure control."

Epilepsy is one of the most common neurological diseases, affecting approximately one in 100 people6. Treatment of partial-onset seizures, the most common type of epilepsy, remains a constant challenge and up to 40% of patients with partial seizures do not achieve seizure control with current anti-epileptics(2).

Additional studies presented at the IEC further reinforce the efficacy and safety of eslicarbazepine acetate in the treatment of partial-onset seizures, with or without secondary generalisation(3,4).

Pooled data from more than 1,000 patients enrolled in th
'/>"/>

SOURCE BIAL
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Demonstrates Efficacy of Pitavastatin in Elderly Patients
2. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
3. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
4. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
5. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
6. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
9. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
10. Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
11. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 2014  Decision Resources Group,s new Manhattan ... that online information and other value-added services ... their offering and support physicians. Physicians who ... rely on websites, mobile apps and other ... physicians are looking to manufacturers to provide ...
(Date:9/15/2014)... , Sept. 15, 2014 myMatrixx has extended ... Stanos with an expanded role that includes direct ... Dr. Stanos, a nationally recognized physiatrist and pain management ... to rehabilitation and workers, compensation, is Board Certified in ... American Board of Pain Medicine and subspecialty boarded by ...
(Date:9/15/2014)... Sept. 15, 2014  Catalist-listed QT Vascular Ltd. ("QT ... developer and manufacturer of minimally invasive medical devices for ... that the Group has enrolled the first European patients ... . Multiple patients have already been enrolled in this ... City Hospital, in Auckland, New Zealand ...
Breaking Medicine Technology:Physician device decision-makers show strong demand for device manufacturer digital content and support 2Physician device decision-makers show strong demand for device manufacturer digital content and support 3myMatrixx Announces Expanded Role for Medical Director Steven P. Stanos, Jr., DO 2First European Patients Enrolled in QT Vascular's ENDURE Trial 2First European Patients Enrolled in QT Vascular's ENDURE Trial 3First European Patients Enrolled in QT Vascular's ENDURE Trial 4First European Patients Enrolled in QT Vascular's ENDURE Trial 5
... , SACRAMENTO, Calif., Nov. 10 The Joint ... Ventricular Assist Device/Destination Therapy certification, allowing the Sacramento ... ventricular assist devices (LVADs) as permanent therapy and ... Medical Center, Sacramento is the only hospital in ...
... Stryker Corporation (NYSE: SYK ) announced today that ... technology firm. OtisMed will focus on customizable instrumentation ... that surgeons and patients realize from Stryker,s Triathlon Knee ... operate as part of Stryker,s Orthopaedics Division and remain ...
Cached Medicine Technology:Sutter Medical Center Receives Certification to Use Ventricular Assist Devices as Destination Therapy 2Stryker Announces Agreements To Acquire Assets 2Stryker Announces Agreements To Acquire Assets 3
(Date:9/15/2014)... 2014 Octo Consulting Group, a ... to the federal government, today announced it is ... Atlanta, Georgia to better serve existing and future ... is credited to the strong growth momentum of ... of management consulting, agile software development, data visualization, ...
(Date:9/15/2014)... By Randy Dotinga ... (HealthDay News) -- Patients prescribed cholesterol-lowering drugs are more ... if the medications are cheaper generic brands, new research ... as statins. Well-known brands include Crestor, Zocor and Lipitor. ... to lower the risk of heart problems due to ...
(Date:9/15/2014)... approximately one out of every 40 individuals in the United ... muscular atrophy (SMA), a neurodegenerative disease that causes muscles to ... have made a recent breakthrough with the development of a ... of the disease. In April, a patent was filed for ... lab is using to fight SMA is to ,repress the ...
(Date:9/15/2014)... Texas (PRWEB) September 16, 2014 ... key market data on the Canada Gynecological Devices ... US dollars, volume (in units) and average prices ... Female Sterilization Devices (Transcervical Sterilization ... and Rings) , Endometrial Ablation Devices ...
(Date:9/15/2014)... September 15, 2014 In order to ... medicine often act conjointly to quantify, define and model ... become an integral part of medical care. , The ... the studies conducted by the non-profit Institute of BioAcoustic ... demonstrated that math can be much more than a ...
Breaking Medicine News(10 mins):Health News:Octo Consulting Group Announces it is Opening Two New Offices in Alexandria, Virginia and Atlanta, Georgia to Better Serve Existing and Future Federal Government Clients 2Health News:Older Patients More Likely to Fill Prescriptions for Generic Statins: Study 2Health News:Older Patients More Likely to Fill Prescriptions for Generic Statins: Study 3Health News:Researcher develops and proves effectiveness of new drug for spinal muscular atrophy 2Health News:Canada Gynecological Devices Market Outlook to 2020 in New Report Available at MarketOptimizer.org 2Health News:Canada Gynecological Devices Market Outlook to 2020 in New Report Available at MarketOptimizer.org 3Health News:Canada Gynecological Devices Market Outlook to 2020 in New Report Available at MarketOptimizer.org 4Health News:Math as Medicine: The Promise of Frequency Domain BioMarkers as a Template to Predict, Enchance and Promote Optimal Health 2Health News:Math as Medicine: The Promise of Frequency Domain BioMarkers as a Template to Predict, Enchance and Promote Optimal Health 3
... Video game makers are now looking to extend their reach beyond ... a really ripe market awaits them. For the aging population in ... water.// ,Leading games manufacturer, Nintendo has sold 3.3 million ... May last. "We wanted to reach out to those who were ...
... uses the construction abilities of tiny viruses to build ... batteries.// , MIT Professors Angela Belcher, Paula ... few genes within common laboratory virus strains were able ... functional electronic device. ,Batteries are made of ...
... Emirates are concerned with the proposal of the Ministry of ... the country.// ,"A committee has been set up ... provides for the private medical sector. This includes the licensing ... and the licensing of the medical or health establishments as ...
... Pink is angry that teenage girls are so obsessed with ... a sex tape.// ,According to contactmusic.com, Pink caused controversy ... in her song "Stupid Girls". But she says there is ... the popularity of Hilton's raunchy homemade film made with her ...
... Association, Les Woolard of Moree says that the Federal Government ... prepared to work in regional areas. // ,According to ... who live in Newcastle, Sydney and Wollongong there are six ... there is only one psychologist. ,He said that ...
... obesity is that the amount of junk food youngsters ... spend// watching television. Researchers analyzed the dietary and viewing habits ... , It was found that consumption of sweets and fizzy ... the idiot box. Researchers at the universities of Aberdeen and ...
Cached Medicine News:Health News:TV Viewing Increases Intake of Junk Food 2
... vascular closure device quickly seals ... procedures, allowing for early ambulation ... creates a mechanical seal by ... bio-absorbable anchor and collagen sponge, ...
These are coronary angiographic catheters used for selective coronary bypass angiography. The catheters curve configuration is ideally suited to select the internal mammary artery....
Femoral selective catheter. Catheter material used is polyurethane (DUCOR). Guidewire campatibility is 0.038". Packaging 5/Box....
Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
Medicine Products: